Clinical Trial

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

Study acronym: CRAVAT
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 19, 2022 (before its estimated January 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neo adjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-11-11; most recent amendment 2022-10-18.
Status change: Not Yet Recruiting → Recruiting 2020-06-25
Trial Details
NCT Number NCT04161664
Lead Sponsor The Netherlands Cancer Institute
Conditions Metastatic Squamous Cell Carcinoma of the Vulva
Enrollment 12 participants
Start Date 2020-01-16
Primary Completion 2024-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2022-10-19